Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Zevra Therapeutics Q4 2023 GAAP EPS $(0.40) Misses $(0.27) Estimate, Sales $13.217M Beat $11.738M Estimate

Author: Benzinga Newsdesk | March 28, 2024 05:05pm
Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.27) by 48.15 percent. The company reported quarterly sales of $13.217 million which beat the analyst consensus estimate of $11.738 million by 12.60 percent. This is a 474.65 percent increase over sales of $2.300 million the same period last year.

Posted In: ZVRA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist